<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909298</url>
  </required_header>
  <id_info>
    <org_study_id>TTP889-202</org_study_id>
    <nct_id>NCT00909298</nct_id>
  </id_info>
  <brief_title>Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)</brief_title>
  <official_title>A Randomized Clinical Trial of Intrinsic Pathway Antagonists in Patients Undergoing Implantation of Left Ventricular Assist Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if post-operative administration of intrinsic&#xD;
      pathway antagonist (TTP889) in patients on Left Ventricular Assist Device (LVAD) support will&#xD;
      result in a 50% reduction of thrombin generation markers at 28 days compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The level of thrombin generation markers</measure>
    <time_frame>28 days following initiation of study drug</time_frame>
    <description>Thrombin-antithrombin complex (TAT)and Prothrombin Fragment 1+2 (F1.2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombin Generation Markers</measure>
    <time_frame>Baseline, Days 1, 3, 5, 7, 14, 21, 28 (±2); and 42 (± 4) days post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Day 1 to Day 42 (± 4) days post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusions of Blood and Blood Products</measure>
    <time_frame>Days 1, 3, 5, 7, 14, 21, 28 (±2); and 42 (± 4) days post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Count</measure>
    <time_frame>Baseline, Days 1, 3, 5, 7, 14, 21, 28 (±2); and 42 (± 4) days post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation Markers</measure>
    <time_frame>Baseline, Days 1, 3, 5, 7, 14, 21, 28 (±2); and 42 (± 4) days post-randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Baseline, Days 1, 3, 5, 7, 14, 21, 28 (±2); and 42 (± 4) days post-randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Coagulation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTP889 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TTP889 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP889</intervention_name>
    <description>300 mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent, release of medical information, and HIPAA forms&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  Male, postmenopausal female, or female who may become pregnant but is using adequate&#xD;
             contraceptive precautions (defined as oral contraceptive, intrauterine devices,&#xD;
             surgical contraception or a combination of a condom and a spermicide), with negative&#xD;
             pregnancy test&#xD;
&#xD;
          -  Implanted with an FDA-approved LVAD (for BTT or DT indication, e.g. HeartMate® XVE)&#xD;
             within 72 hours prior to randomization, and able to receive the first dose of study&#xD;
             drug by 72 hours (+6 hours) post LVAD implantation&#xD;
&#xD;
          -  Post-op hemostasis adequate for starting low level anticoagulation (as assessed by&#xD;
             surgeon)&#xD;
&#xD;
          -  Extubated and able to take oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of active bleeding within 24 hours prior to randomization&#xD;
&#xD;
          -  History of a platelet disorder, including but not limited to thrombocytopenia and&#xD;
             thrombasthenia&#xD;
&#xD;
          -  Thrombocytopenia with platelets &lt;80,000/ml within 48 hours prior to randomization&#xD;
&#xD;
          -  History of an inherited or acquired coagulation disorder&#xD;
&#xD;
          -  Hemoglobin &lt;8 g/dL (4.85 mmol/L) or hematocrit &lt;26% within 24 hours prior to&#xD;
             randomization&#xD;
&#xD;
          -  Clinical indication for (or the intention to use) standard anticoagulation therapy at&#xD;
             time of randomization (e.g., atrial fibrillation or DVT)&#xD;
&#xD;
          -  Intention to treat with more than 325 mg aspirin daily&#xD;
&#xD;
          -  Any clinical requirement or intention to treat with phenytoin, tolbutamide or warfarin&#xD;
             post randomization&#xD;
&#xD;
          -  RVAD support at the time of randomization&#xD;
&#xD;
          -  Estimated glomerular filtration rate (GFR) ≤30 ml/min (by Cockcroft-Gault formula), or&#xD;
             any form of dialysis within 48 hours prior to randomization&#xD;
&#xD;
          -  Evidence of intrinsic hepatic disease as defined as biopsy proven liver cirrhosis; or&#xD;
             liver enzyme values (AST or ALT) that are &gt;3 times the upper limit of normal; or Total&#xD;
             Bilirubin &gt;1.5 times the upper limit of normal (with the exception of Gilbert's&#xD;
             Syndrome) within 3 days prior to randomization&#xD;
&#xD;
          -  Active systemic infection, in the judgment of the investigator, within 3 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Stroke or transient ischemic attack (TIA) within 6 months prior to randomization&#xD;
&#xD;
          -  History of intracranial hemorrhage or gastrointestinal bleed within 3 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Alzheimer's disease, or any other form of irreversible dementia&#xD;
&#xD;
          -  History of psychiatric disease (including drug or alcohol abuse) that may impair&#xD;
             compliance with the study protocol&#xD;
&#xD;
          -  Pregnant or breastfeeding at time of randomization&#xD;
&#xD;
          -  Received investigational intervention within 30 days prior to randomization&#xD;
&#xD;
          -  Body weight &lt; 45 Kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Moskowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshifumi Naka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Presbyterian Hospital / Columbia University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital / Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>May 27, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <disposition_first_submitted>July 15, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>July 15, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 20, 2010</disposition_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alan Moskowitz, MD Co-Director</name_title>
    <organization>International Center for Health Outcomes and Innovation Research</organization>
  </responsible_party>
  <keyword>Left ventricular assist devices</keyword>
  <keyword>Cardiac Disease</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Anticoagulant for Left Ventricular Assist Devices</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

